Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination

Intravesical bacillus Calmette-Guérin (BCG) immunotherapy results in neutrophil recruitment and subsequent secretion of cytokines to eliminate non-muscle invasive bladder cancer cells. However, bladder cancer cells often resist BCG immunotherapy. Thus, understanding the mechanism of action of BCG, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jinesh G., Goodwin, Kamat, Ashish M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494630/
https://www.ncbi.nlm.nih.gov/pubmed/23170264
http://dx.doi.org/10.4161/onci.20928
_version_ 1782249418654744576
author Jinesh G., Goodwin
Kamat, Ashish M.
author_facet Jinesh G., Goodwin
Kamat, Ashish M.
author_sort Jinesh G., Goodwin
collection PubMed
description Intravesical bacillus Calmette-Guérin (BCG) immunotherapy results in neutrophil recruitment and subsequent secretion of cytokines to eliminate non-muscle invasive bladder cancer cells. However, bladder cancer cells often resist BCG immunotherapy. Thus, understanding the mechanism of action of BCG, and designing appropriate combination therapies might help to overcome BCG resistance and redirect neutrophils against bladder cancer cells.
format Online
Article
Text
id pubmed-3494630
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34946302012-11-20 Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination Jinesh G., Goodwin Kamat, Ashish M. Oncoimmunology Author's View Intravesical bacillus Calmette-Guérin (BCG) immunotherapy results in neutrophil recruitment and subsequent secretion of cytokines to eliminate non-muscle invasive bladder cancer cells. However, bladder cancer cells often resist BCG immunotherapy. Thus, understanding the mechanism of action of BCG, and designing appropriate combination therapies might help to overcome BCG resistance and redirect neutrophils against bladder cancer cells. Landes Bioscience 2012-10-01 /pmc/articles/PMC3494630/ /pubmed/23170264 http://dx.doi.org/10.4161/onci.20928 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Jinesh G., Goodwin
Kamat, Ashish M.
Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination
title Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination
title_full Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination
title_fullStr Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination
title_full_unstemmed Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination
title_short Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination
title_sort redirecting neutrophils against bladder cancer cells by bcg and smac mimetic combination
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494630/
https://www.ncbi.nlm.nih.gov/pubmed/23170264
http://dx.doi.org/10.4161/onci.20928
work_keys_str_mv AT jineshggoodwin redirectingneutrophilsagainstbladdercancercellsbybcgandsmacmimeticcombination
AT kamatashishm redirectingneutrophilsagainstbladdercancercellsbybcgandsmacmimeticcombination

Ejemplares similares